WASHINGTON (Reuters) -The Food and Drug Administration is expected to authorize the use of the Pfizer (NYSE:PFE) COVID-19... By Hyonhee Shin SEOUL (Reuters) - One dose of COVID-19 vaccines from ...

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Uncle Sam’s abiding ambivalence about having close ties with corporate America is getting some fresh, albeit unwelcome, ...

Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...

The cause for his optimism was the fact that more than 182 million Americans had received at least one shot of the new COVID-19 vaccines, including nearly 90 percent of seniors and 70 percent of ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...

BANGKOK--Thai Prime Minister Prayuth Chan-ocha, under intense criticism for failing to secure adequate supplies of coronavirus ... National Vaccine Institute is negotiating with Pfizer over ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...